Discover and read the best of Twitter Threads about #STK11
Most recents (3)
The #AACR23 abstracts will be accessible from here (not all sessions populated yet at the time of this tweet)
abstractsonline.com/pp8/#!/10828/
abstractsonline.com/pp8/#!/10828/
"new drugs on the horizon":
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND01 - ABBV-319: A first-in-class Glucocorticoid Receptor Modulator (GRM) agonist #ADC for the treatment of B-cell malignancies $ABBV
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
Major update for small cell #lung cancer! #LCSM
With @juliensage + @FoundationATCG, our paper now on @bioRxiv:
►Genomic analysis of *3,600* pts with SCLC; largest SCLC study to date!
►Multiple interesting findings discussed in this 🧵
biorxiv.org/content/10.110…
With @juliensage + @FoundationATCG, our paper now on @bioRxiv:
►Genomic analysis of *3,600* pts with SCLC; largest SCLC study to date!
►Multiple interesting findings discussed in this 🧵
biorxiv.org/content/10.110…
🧵2
This study is unique in many ways:
> The #SCLC cohort studied came mostly from community sites --> representing a more typical “real-world” cohort of SCLC.
> The genomic data are tied to clinical data + outcomes.
#LCSM
This study is unique in many ways:
> The #SCLC cohort studied came mostly from community sites --> representing a more typical “real-world” cohort of SCLC.
> The genomic data are tied to clinical data + outcomes.
#LCSM
🧵3
To the best of our knowledge, our study analyzes the largest number of SCLC tumors from African ancestry to date:
> n=256 AFR cases
> 7.1% of the entire cohort
#Diversity in clinical studies is critical!!
See tweet 🧵9 for more details.
To the best of our knowledge, our study analyzes the largest number of SCLC tumors from African ancestry to date:
> n=256 AFR cases
> 7.1% of the entire cohort
#Diversity in clinical studies is critical!!
See tweet 🧵9 for more details.
@TumorBoardTues @JohnEbbenMDPhD 1/14 Case Presentation
63 👱♂️ p/w LUE & LLE weakness. CT 🧠 w/ R frontal mass.
Craniotomy and 🔪 resection ➡️ metastatic poorly-differentiated carcinoma. CT C/A/P normal.
❓What would you do next? 🧐
@NSethakorn @NarjustDumaMD @HamidEmamekhoo @KariWisinski_MD @HemOncFellows
63 👱♂️ p/w LUE & LLE weakness. CT 🧠 w/ R frontal mass.
Craniotomy and 🔪 resection ➡️ metastatic poorly-differentiated carcinoma. CT C/A/P normal.
❓What would you do next? 🧐
@NSethakorn @NarjustDumaMD @HamidEmamekhoo @KariWisinski_MD @HemOncFellows
@TumorBoardTues @JohnEbbenMDPhD @NSethakorn @NarjustDumaMD @HamidEmamekhoo @KariWisinski_MD @HemOncFellows 2/14 #TumorBoardTuesday #OncTwitter #CUP
This is cancer of unknown primary (CUP)! ☕️
Initial evaluation of CUP includes:
🔹 H&P
🔹 CBC, CMP 🧪
🔹 CT C/A/P 📷
🔹 IHC 🔬
🔹 Optional ➡️ tumor markers, endoscopy, mammogram, PET/CT
@SamLubner @loconte @uw_hemeoncpc @OncoAlert
This is cancer of unknown primary (CUP)! ☕️
Initial evaluation of CUP includes:
🔹 H&P
🔹 CBC, CMP 🧪
🔹 CT C/A/P 📷
🔹 IHC 🔬
🔹 Optional ➡️ tumor markers, endoscopy, mammogram, PET/CT
@SamLubner @loconte @uw_hemeoncpc @OncoAlert
@TumorBoardTues @JohnEbbenMDPhD @NSethakorn @NarjustDumaMD @HamidEmamekhoo @KariWisinski_MD @HemOncFellows @SamLubner @loconte @uw_hemeoncpc @OncoAlert 3/14 #TumorBoardTuesday
Other history ➡️ no other sxs, 🚬 30 pack-years, no family history of cancer
The patient’s IHC findings:
🔸 CAM5.2 ➕
🔸 CK7 ➕
🔸 CK20 ➖
🔸 All other markers ➖
❓What primary site are you most suspicious of? 🕵️
@UWiscPathology @erik_rannheim
Other history ➡️ no other sxs, 🚬 30 pack-years, no family history of cancer
The patient’s IHC findings:
🔸 CAM5.2 ➕
🔸 CK7 ➕
🔸 CK20 ➖
🔸 All other markers ➖
❓What primary site are you most suspicious of? 🕵️
@UWiscPathology @erik_rannheim
